Open an account

Castle Biosciences

CSTL · NASDAQ

$33.15+$0.985 (+3.06%)TodayMarket closed ·
Prev close $32.17

About CSTL

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 883 full-time employees. The company went IPO on 2019-07-25. The firm offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).

Employees
942
Headquarters
Friendswood, Texas
Listed
Jul 25, 2019
Sector
Health Care
Industry
Health Care Providers & Services
Website
castlebiosciences.com

CSTL key statistics

Market cap
1.01B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
374.58K
Volume
272.58K
Open price
$32.65
High today
$33.55
Low today
$32.09
52 Week high
$44.28
52 Week low
$17.72

Castle Biosciences (CSTL) at a glance

As of Oct 20, 2026, Castle Biosciences (CSTL) shares are priced at $33.15, giving the company a market cap of 1.01B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $32.09 and $33.55. The current price is 3.3% above the day's low and 1.2% below its high.

Volume so far is 272.58K shares, below the average of 374.58K shares a day.

Over the past year Castle Biosciences has ranged from $17.72 to $44.28, and now sits 58% of the way up that range.

Castle Biosciences met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.4148.

The average analyst price target is $46.01, 38.8% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $46.01
Low
$35.35
Now
$33.15
High
$59.85

CSTL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 166.3% on average.

  1. Q3 FY24: reported $0.08 per share against an estimate of -$0.065
  2. Q4 FY24: reported $0.33 per share against an estimate of $0.0501
  3. Q1 FY25: reported -$0.20 per share against an estimate of -$0.0725
  4. Q2 FY25: reported $0.15 per share against an estimate of -$0.5338
  5. Q3 FY25: reported -$0.02 per share against an estimate of -$0.5329
  6. Q4 FY25: reported -$0.08 per share against an estimate of -$0.292
  7. Q1 FY26: reported -$0.49 per share against an estimate of -$0.4998
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.4148

CSTL news

  • Press releasePRNewswire

    Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026

  • Press releasePRNewswire

    ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus

  • Press releasePRNewswire

    Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

  • Press releasePRNewswire

    New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

  • Press releasePRNewswire

    New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

  • Press releasePRNewswire

    Castle Biosciences to Open New Laboratory Facility in Scottsdale

  • Press releasePRNewswire

    New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus

  • Press releasePRNewswire

    JAAD Publication Shows Improved Performance of DecisionDx®-SCC

Similar companies

Companies in the same industry as Castle Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.